The latest business news around the world. Written by Market Business News's very own editorial team to deliver reliable, up to date, and honest news.

Sanofi S.A. – Company Information

0

Sanofi S.A. – Company Overview 

Sanofi logo
Company Sanofi S.A.
Headquarters 54, Rue La Boétie, 75008 Paris, France
CEO Olivier Brandicourt
CFO Jérôme Contamine
Industry Pharmaceutical
Type Public
Founder Jean-François Dehecq and Jean-René Sautier
Founded 1973
NYSE stock symbol SNY
Net Sales €34,542 million EUR (2015)
Operating income €5,624 million EUR (2015)
Net income €4,388 million EUR (2015)
Employees 115,631 (2015)
Website http://en.sanofi.com/
IR contact number +33 (0)1 53 77 40 00
IR email address [email protected]

Sanofi S.A. focuses on the development and production of prescription drugs, over-the-counter drugs, and vaccines. Some of its most notable products are:

  • Zolpidem (Ambien) – an anxiolytic sedative
  • Glimepiride (Amaryl) – a sulfonylureas drug for type 2 diabetes mellitus
  • Enoxaparin (Lovenox) – drug for thrombosis
  • Insulin (Lantus) – drug for diabetes

In 1973 Sanofi was created as a subsidiary of Elf Aquitaine (French oil company) following its acquisition of the pharmaceutical company Labaz.

In 1999 Sanofi merged with a former subsidiary of L’Oréal called Synthélabo, to create Sanofi-Synthélabo. 

In 2004 Sanofi-Synthélabo merged with Aventis and changed its name to Sanofi-Aventis.

However, in 2011 the company decided to remove the -Aventis suffix. Partly because Sanofi (on its own) is easier to pronounce in countries such as China.

Sanofi has acquired the following companies since 2009:

  • Zentiva
  • Medley (A Brazilian pharmaceutical company)
  • Chattem, Inc.
  • BMP Sunstone Corporation
  • Genzyme Corporation (a biotechnology group)

Sanofi history

Sanofi is the result of several mergers and acquisitions.


Sanofi S.A. – Financial Results

Key figures (in millions of EUR) 2015* 2014*
Net sales €34,542 €31,694
Gross profit €23,942 €21,769
Operating income €5,624 €6,064
Net income €4,388 €4,509
Total assets €102,321 €97,392
Cash and cash equivalents at beginning of period €7,341 €8,257
Cash and cash equivalents at end of period €9148 $7,341

*For the years ended December 31, 2015 and 2014

Source: “Sanofi S.A. – 2015 Form 20-F”


Sanofi S.A. – Live Stock Market Data